MX2021012923A - Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas. - Google Patents
Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas.Info
- Publication number
- MX2021012923A MX2021012923A MX2021012923A MX2021012923A MX2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A MX 2021012923 A MX2021012923 A MX 2021012923A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained
- microparticles containing
- preparation
- release microparticles
- method therefor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
De acuerdo con las micropartículas de liberación sostenida que contienen deslorelina, y un método de preparación de las mismas, de la presente invención, se proporcionan micropartículas de liberación sostenida que contienen deslorelina en una formulación para la administración subcutánea, de modo que se puede aliviar el dolor durante la administración a los animales, y un efecto de castración química puede durar de 2 a 36 meses. Además, la presente invención es efectiva como agente de castración química durante 2 a 8 meses, de modo que tiene un excelente efecto de eliminación del olor a verraco.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190050437A KR102249104B1 (ko) | 2019-04-30 | 2019-04-30 | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 |
PCT/KR2020/000657 WO2020222399A1 (ko) | 2019-04-30 | 2020-01-14 | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012923A true MX2021012923A (es) | 2021-11-17 |
Family
ID=73028838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012923A MX2021012923A (es) | 2019-04-30 | 2020-01-14 | Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220202894A1 (es) |
EP (1) | EP3949951A4 (es) |
JP (1) | JP7253287B2 (es) |
KR (1) | KR102249104B1 (es) |
CN (1) | CN113747884A (es) |
AU (1) | AU2020266058B2 (es) |
BR (1) | BR112021021599A2 (es) |
CA (1) | CA3137819C (es) |
CL (1) | CL2021002761A1 (es) |
IL (1) | IL287361A (es) |
MX (1) | MX2021012923A (es) |
PE (1) | PE20220491A1 (es) |
SG (1) | SG11202111521WA (es) |
WO (1) | WO2020222399A1 (es) |
ZA (1) | ZA202108300B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230124229A (ko) * | 2022-02-18 | 2023-08-25 | (주)인벤티지랩 | 데슬로렐린을 포함하는 서방성 주사용 조성물 |
WO2024003291A1 (en) | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction |
WO2024003288A1 (en) * | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin for attenuation of animal urine odor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1045625A (ja) * | 1996-04-30 | 1998-02-17 | Takeda Chem Ind Ltd | 医薬組成物 |
EP1007080B1 (en) * | 1996-08-30 | 2007-04-18 | Peptech Limited | Formulation for the sustained release of peptide agonists and analogues of GnRH |
JP4166590B2 (ja) * | 2003-02-04 | 2008-10-15 | 独立行政法人科学技術振興機構 | ダブルエマルション・マイクロカプセル生成装置 |
DK1824460T3 (en) * | 2004-11-10 | 2015-01-19 | Tolmar Therapeutics Inc | Stabilized polymeric delivery system |
AU2007207618B2 (en) * | 2006-01-18 | 2011-03-24 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical compositions with enhanced stability |
BRPI0902699A2 (pt) | 2009-07-28 | 2011-04-12 | Marcelo Vivacqua | método quìmico para esterilização sexual e eliminação da libido em mamìferos do sexo masculino |
KR101583351B1 (ko) * | 2014-11-28 | 2016-01-07 | 동국제약 주식회사 | 초기 방출 억제 및 잔류용매 제거율을 향상시킨 서방출성 미립구 및 이의 제조방법 |
CN105287390A (zh) * | 2015-11-20 | 2016-02-03 | 北京博恩特药业有限公司 | 一种长效醋酸亮丙瑞林微球及其制备方法 |
WO2017150824A1 (ko) * | 2016-03-03 | 2017-09-08 | 가천대학교 산학협력단 | 마이크로 니들 및 이의 제조방법 |
-
2019
- 2019-04-30 KR KR1020190050437A patent/KR102249104B1/ko active IP Right Grant
-
2020
- 2020-01-14 CN CN202080031675.6A patent/CN113747884A/zh active Pending
- 2020-01-14 JP JP2021563253A patent/JP7253287B2/ja active Active
- 2020-01-14 BR BR112021021599A patent/BR112021021599A2/pt unknown
- 2020-01-14 AU AU2020266058A patent/AU2020266058B2/en active Active
- 2020-01-14 WO PCT/KR2020/000657 patent/WO2020222399A1/ko unknown
- 2020-01-14 MX MX2021012923A patent/MX2021012923A/es unknown
- 2020-01-14 US US17/605,185 patent/US20220202894A1/en active Pending
- 2020-01-14 PE PE2021001759A patent/PE20220491A1/es unknown
- 2020-01-14 EP EP20799171.2A patent/EP3949951A4/en active Pending
- 2020-01-14 CA CA3137819A patent/CA3137819C/en active Active
- 2020-01-14 SG SG11202111521WA patent/SG11202111521WA/en unknown
-
2021
- 2021-10-18 IL IL287361A patent/IL287361A/en unknown
- 2021-10-20 CL CL2021002761A patent/CL2021002761A1/es unknown
- 2021-10-27 ZA ZA2021/08300A patent/ZA202108300B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3137819A1 (en) | 2020-11-05 |
US20220202894A1 (en) | 2022-06-30 |
AU2020266058B2 (en) | 2023-04-06 |
JP7253287B2 (ja) | 2023-04-06 |
KR102249104B1 (ko) | 2021-05-07 |
CL2021002761A1 (es) | 2022-06-03 |
ZA202108300B (en) | 2023-01-25 |
IL287361A (en) | 2021-12-01 |
EP3949951A1 (en) | 2022-02-09 |
BR112021021599A2 (pt) | 2021-12-21 |
CN113747884A (zh) | 2021-12-03 |
SG11202111521WA (en) | 2021-11-29 |
WO2020222399A1 (ko) | 2020-11-05 |
JP2022530878A (ja) | 2022-07-04 |
KR20200126599A (ko) | 2020-11-09 |
EP3949951A4 (en) | 2023-01-18 |
CA3137819C (en) | 2024-01-09 |
AU2020266058A1 (en) | 2021-11-18 |
PE20220491A1 (es) | 2022-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012923A (es) | Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas. | |
MX2020010603A (es) | Extracto de cáñamo para tratamiento de dolor en animales. | |
JOP20190146A1 (ar) | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد | |
MX2022000027A (es) | Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales. | |
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
MX2022010274A (es) | Uso de dexmedetomidina sublingual para el tratamiento de la agitacion. | |
MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
PH12021550537A1 (en) | Oral formulations of kappa opioid receptor agonists | |
NZ792518A (en) | Formulations for administration of eflornithine | |
EP4338804A3 (en) | Epinephrine spray formulations | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
WO2016168553A8 (en) | Deuterated obeticholic acid | |
EP4061802A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVED ABSORPTION OF ACTIVE INGREDIENTS FOR ANIMAL HEALTH AND NUTRITION | |
PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
ZA202104960B (en) | Methods of treating pain with a thiazoline anti-hyperalgesic | |
RU2017105451A (ru) | Иммуногенная композиция lhrh и ее применение у свиней | |
UA112418C2 (uk) | Терапевтичний болезаспокійливий засіб | |
MX2020012805A (es) | Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos. | |
MX2022005596A (es) | Regimen de dosificacion para agentes anti-dll3. | |
NZ733658A (en) | Compositions and methods for chronic use of a weight-gaining compound | |
MX2020010243A (es) | Composiciones bucales y metodos para animales. | |
MX2021008687A (es) | Una composicion para el tratamiento de la periodontitis y la regeneracion de la papila interdental. | |
MX2020013684A (es) | Formulaciones/composiciones que comprenden ibrutinib. | |
MX2023002625A (es) | Composiciones y metodos para proporcionar beneficios para la salud en un animal. |